Stories related to Innovation

Responding to new public health concerns

We are faced not only with existing infectious diseases but also the rise of new ones.

Sustainability at Roche: Our impact

Engaging with stakeholders is crucial to create sustainable value. Stakeholder engagement enables us to jointly develop solutions.

Roche at RCOG

The annual Royal College of Obstetrics and Gynaecology (RCOG) World Congress brings together health professionals to learn from each other and exchange views.

The NT-proBNP Story

Biomarkers play a crucial role in Roche’s commitment to personalised healthcare. To find them, we rely on the promising research of our external partners.

Better together: Helping one million people with diabetes

Ask anybody with diabetes: managing it is time consuming, exhausting and very annoying.

Of bonds and benefits

Two made-in-Japan collaborations strengthen both Roche and its partners.

Highlights Annual Report 2017

Read the incredible stories behind the numbers.

Pioneering a new era in cancer diagnostics

Effective therapies start with an accurate diagnosis. Diagnostics advancements are helping patients to receive personalised treatments.

Roche at J.P. Morgan Healthcare Conference

Collaborating to drive the future of personalised healthcare

How decades of blood cancer research is paying off

We explore how a growing understanding of the biology of blood cancers is transforming the development and delivery of treatments for patients.

Rising to the challenge

As multidrug resistant strains of bacteria are posing a growing threat to human health worldwide, our scientists are working hard on the next generation of antibiotics and diagnostic tests.

The value of diagnostics in heart failure management

Heart failure affects millions of people and despite improvement in care, management remains challenging. Biomarkers can help patients at every stage of care.

Integrated, connected laboratories: a new era in lab testing

A new era in lab testing is tackling today’s challenges and tomorrow’s needs in a rapidly shifting global health landscape.

Changing the perspective on lung cancer: a story of hope and survival

How does understanding each lung cancer’s unique footprint set you on the right path for a promising new future? Find out...

MS measurements explained

How we define the ways in which multiple sclerosis can be measured.

Roche at the World Congress on Lung Cancer

Check out how we are transforming the diagnosis and management of lung cancer.

Keeping every drop safe

Screening tests protect blood supplies from contamination by the Zika virus.

Roche at ESMO

Learn about how we are leading the science of cancer to improve outcomes for patients today and tomorrow.

The realities of pursuing the cure for cancer

Cindy Perettie, our Global Head of Oncology Strategy, provides her personal perspective on the challenges of leading the cure for cancer.

Smart technology speeds up development of antibiotics

Roche and British biotechnology company Discuva are collaborating to develop new classes of antibiotics for the treatment of multidrug-resistant bacteria.

Future of immunology: It’s all about balance

David M. Lee, Head of Immunology, Inflammation and Infectious Diseases, shares personal experience as a physician and talks about new treatment approaches for immune-mediated diseases.

‘Accelerators and brakes’ to restore immune balance

Roche strategy in Immunology is to make use of the growing scientific understanding of immune pathways and to selectively manipulate these in order to restore immune balance.

EuroMedLab 2017: transforming laboratory science

Held every two years, EuroMedLab is one of the most influential in vitro diagnostics events worldwide.

Fighting antimicrobial resistance with diagnostics

Antimicrobial resistance is a global and continuously raising global health challenge. Here’s what we are doing to address this problem.

A new strategy for cervical cancer prevention

Learn how new screening, triage and diagnostic tests help clinicians decide which women to treat for cervical cancer.

Our response to cancer always starts with the science

Targeting cancer demands a deep understanding of its complexities. Our researchers have the freedom to explore cutting-edge science & technology to achieve this.

Organs-on-a-Chip technology

Tiny labs made of plastic simulate the human body- the Organs-on-a-Chip technology shows new approaches to obtain human-relevant information on a potential drug.

Annual Report 2016 highlights

Creating value through partnerships

Partnering builds on our culture, one in which we listen to a potential partner and structure a collaboration that meets both parties’ needs.

No woman needs to die from cervical cancer

Despite being highly preventable through screening,treatment and vaccination, cervical cancer remains one of the most common and deadly women’s cancer.

Spotlight on comprehensive genomic profiling

Comprehensive genomic profiling provides valuable information that can help determine the best possible treatment for each patient.

Annual Report 2015 highlights

A quick journey through Roche’s business year at a glance.

A new era in cancer diagnostics: a personal perspective

Dr Walter Koch, Head of Research at Roche Molecular Diagnostics, explains how his “dream job” is helping push into new frontiers of science.

How Roche Partnering succeeds in the quest for innovation

Excellence in science

In our pursuit of excellence in science, our distinctiveness rests on four key elements: an exceptionally broad and deep understanding of molecular biology, the seamless integration of our pharmaceuticals and diagnostics capabilities, a diversity of approaches to maximise innovation, and a long-term orientation.

“It was a dream come true to have such a direct impact on women’s health.”

Catherine, a trained gynecologist, who is passionate about women’s health shares why she joined Roche to work on a cervical cancer test.

To understand biology, you need to be able to measure it.

A biomarker model that is almost 100% predictive

Breast cancer: Know more

Despite the significant progress made over the last few decades in patient outcomes, breast cancer is still the most common cancer affecting women.

A blood screening centre that raised the bar

Donated blood should be screened for infections that can be transmitted through transfusions. Learn how we're helping blood banks keep a safe blood supply.

What's the prognosis for diagnostic testing in lung cancer?

Being able to test biopsy tissue for all of the targeted therapies being developed is rapidly becoming a significant practical challenge - Roche Group is working on innovative solutions.

Keeping cancer immunotherapy personal

Fighting cancer using patients own immune system is a concept that has been around for a long time, and real advances in our understanding about how to do this have been made over the last 10-15 years.

Personalised healthcare inconceivable without biomarkers

In addition to promoting an exchange of expertise, the main goal of the Oncology Biomarker Symposium was to grow a network across functions, divisions and geographic sites. Biomarker tests can only parallel drug development and, ideally, be launched alongside treatments if Pharmaceuticals and Diagnostics work closely together.

Small efforts make a difference in the fight against cancer

February 4 was World Cancer Day. Just another day in the calendar! Not really, if you consider that it is a reminder of the fact that an estimated 13 million plus new cases occur every year